Sanofi taps Charmeil as emerging-markets vax chief; Novartis' Afintor delays breast cancer;

@FiercePharma: Drug, device reps add iPads to tool belt. Article | Follow @FiercePharma

> Sanofi-Aventis has named a new emerging markets-focused chief for its vaccines division, Olivier Charmeil, who's currently responsible for pharmaceutical operations in Asia-Pacific and Japan. Story

> Swiss drugmaker Novartis said the addition of its Afinitor to hormonal therapy delayed disease progression in breast cancer in a mid-phase study, bringing the potential blockbuster one step closer to gaining approval for this very common form of cancer. Report

> Dutch biotech firm Crucell's chief executive urged shareholders to accept U.S. healthcare group Johnson & Johnson's long-awaited 1.75 billion euro bid. News

> Shares of Adcock Ingram tumbled as much as 4.1 percent after the drugmaker said South Africa would ban three drugs that contributed $29 million to its sales due to safety concerns. Story

> European drugs regulators said they are starting a review of the safety of somatropin-containing medicines after a study suggested the growth hormone treatments increased the risk of death. Report

Biotech News

 @FierceBiotech: Orexigen endorsement raises expectations on obesity drug deals. Story  | Follow @FierceBiotech

 @JohnCFierce: Shrinking and forced to give up China buyout, investors now pushing Charles River Labs to put itself up for sale. News | Follow @JohnCFierce

> Restructuring rejection forces Molecular Insight to declare bankruptcy. Item 

> MorphoSys unit, Pfizer ink Slonomics pact. Story 

> Pfizer halts Phase III trial, withdraws Thelin. Report 

> Ramius sweetens offer for Cypress. News 

And Finally... Indian drugmakers are experimenting with design to distinguish products from round and rectangular pills, adopting dumbbell, flower, lollipop or symbol X shapes. Report